Demirkazık A - Search Results

1

The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.

Ürun Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG, Şenler FC, Demirkazık A, İçli F. Ürun Y, et al. Among authors: demirkazik a. Exp Oncol. 2015 Mar;37(1):53-7. Exp Oncol. 2015. PMID: 25804233 Free article.

2

The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.

Karaağaç M, Geredeli Ç, Yıldırım MS, Altınok T, Dede İ, İnal A, Zamani AG, Kaya B, Demirkazık A, Artaç M. Karaağaç M, et al. Among authors: demirkazik a. J Cancer Res Ther. 2023 Jul-Sep;19(5):1248-1254. doi: 10.4103/jcrt.jcrt_1657_21. J Cancer Res Ther. 2023. PMID: 37787291 Free article.

3

Primary gastrointestinal lymphomas in Turkey: a retrospective analysis of clinical features and results of treatment.

Dinçol D, Içli F, Erekul S, Günel N, Karaoğuz H, Demirkazik A. Dinçol D, et al. Among authors: demirkazik a. J Surg Oncol. 1992 Dec;51(4):270-3. doi: 10.1002/jso.2930510414. J Surg Oncol. 1992. PMID: 1434660

4

Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.

Içli F, Günel N, Dinçol D, Karaoğuz H, Demirkazik A. Içli F, et al. Among authors: demirkazik a. J Surg Oncol. 1992 Aug;50(4):251-3. doi: 10.1002/jso.2930500411. J Surg Oncol. 1992. PMID: 1640710 Clinical Trial.

5

Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.

Icli F, Karaoguz H, Dincol D, Gunel N, Demirkazik A. Icli F, et al. Among authors: demirkazik a. J Surg Oncol. 1991 Nov;48(3):199-201. doi: 10.1002/jso.2930480312. J Surg Oncol. 1991. PMID: 1943117

6

Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.

Dinçol D, Içli F, Karaoğuz H, Cay F, Arican A, Demirkazik A, Akbulut H. Dinçol D, et al. Among authors: demirkazik a. Acta Oncol. 1995;34(7):937-40. doi: 10.3109/02841869509127208. Acta Oncol. 1995. PMID: 7492384

7

Severe vascular toxicity associated with cisplatin-based chemotherapy.

Içli F, Karaoğuz H, Dinçol D, Demirkazik A, Günel N, Karaoğuz R, Uner A. Içli F, et al. Among authors: demirkazik a. Cancer. 1993 Jul 15;72(2):587-93. doi: 10.1002/1097-0142(19930715)72:2<587::aid-cncr2820720242>3.0.co;2-v. Cancer. 1993. PMID: 8319192 Review.

8

Two dose levels of ifosfamide in malignant mesothelioma.

Içli F, Karaoğuz H, Hastürk S, Kurt B, Akbulut H, Dinçol D, Demirkazik A, Cay F, Akyar S. Içli F, et al. Among authors: demirkazik a. Lung Cancer. 1996 Sep;15(2):207-13. doi: 10.1016/0169-5002(96)00584-3. Lung Cancer. 1996. PMID: 8882987 Clinical Trial.

9

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer.

Içli F, Karaoguz H, Akbulut H, Dinçol D, Demirkazik A, Cay F. Içli F, et al. Among authors: demirkazik a. J Surg Oncol. 1997 Apr;64(4):318-23. doi: 10.1002/(sici)1096-9098(199704)64:4<318::aid-jso13>3.0.co;2-z. J Surg Oncol. 1997. PMID: 9142190 Clinical Trial.

10

Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) +/- bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey.

Dinçol D, Akbulut H, Içli F, Samur M, Karaoğuz H, Demirkazik A, Cay F. Dinçol D, et al. Among authors: demirkazik a. Oncology. 1997 Sep-Oct;54(5):376-9. doi: 10.1159/000227722. Oncology. 1997. PMID: 9260598

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters